NewAmsterdam Pharma (NAMS) Competitors $21.28 -0.53 (-2.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.28 0.00 (0.00%) As of 08/1/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, RGC, RVMD, GRFS, and TGTXShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has preferable valuation & earnings, VRNA or NAMS? Verona Pharma PLC American Depositary Share has higher earnings, but lower revenue than NewAmsterdam Pharma. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M211.78-$173.42M-$2.00-52.59NewAmsterdam Pharma$47.14M50.68-$241.60M-$1.88-11.32 Do institutionals & insiders believe in VRNA or NAMS? 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are owned by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is VRNA or NAMS more profitable? Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -397.45%. NewAmsterdam Pharma's return on equity of -37.34% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% NewAmsterdam Pharma -397.45%-37.34%-33.45% Do analysts prefer VRNA or NAMS? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, indicating a potential upside of 3.63%. NewAmsterdam Pharma has a consensus price target of $41.30, indicating a potential upside of 94.08%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the media prefer VRNA or NAMS? In the previous week, Verona Pharma PLC American Depositary Share had 8 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Verona Pharma PLC American Depositary Share and 3 mentions for NewAmsterdam Pharma. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.45 beat NewAmsterdam Pharma's score of 0.69 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, VRNA or NAMS? Verona Pharma PLC American Depositary Share has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. SummaryNewAmsterdam Pharma beats Verona Pharma PLC American Depositary Share on 9 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.45B$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-11.328.9728.6723.80Price / Sales50.68639.67422.3188.12Price / CashN/A157.7635.4557.96Price / Book2.604.838.275.55Net Income-$241.60M$31.62M$3.24B$259.03M7 Day Performance-9.83%-5.28%-3.63%-4.56%1 Month Performance12.24%4.38%4.40%4.49%1 Year Performance25.03%-2.49%25.97%18.05% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.1898 of 5 stars$21.28-2.4%$41.30+94.1%+23.4%$2.45B$47.14M-11.324Upcoming EarningsVRNAVerona Pharma PLC American Depositary Share2.1781 of 5 stars$104.90flat$109.00+3.9%+365.2%$8.93B$42.28M-52.4530Positive NewsUpcoming EarningsShort Interest ↑BBIOBridgeBio Pharma4.706 of 5 stars$45.90-1.3%$61.50+34.0%+80.9%$8.83B$221.90M-13.00400Upcoming EarningsAnalyst ForecastBPMCBlueprint Medicines1.0958 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences1.8308 of 5 stars$11.48+0.3%$16.50+43.7%+6.5%$7.78B$29.05M-45.92860Upcoming EarningsLEGNLegend Biotech3.5818 of 5 stars$42.23+1.5%$73.33+73.7%-29.5%$7.64B$627.24M-71.582,609Positive NewsELANElanco Animal Health3.7888 of 5 stars$14.67-0.8%$16.00+9.1%+5.9%$7.34B$4.44B19.829,000Positive NewsUpcoming EarningsRGCRegencell Bioscience0.0453 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Positive NewsRVMDRevolution Medicines4.4642 of 5 stars$38.42+0.3%$68.91+79.4%-19.1%$7.13B$11.58M-9.61250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.0861 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.83B$7.81B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0717 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$6.02B$329M157.96290Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts